In the quiet ledgers of institutional ownership, a modest Pittsburgh-style wealth firm, Perigon Wealth Management, has taken a small position in Vera Therapeutics, a clinical-stage biotechnology company working on treatments for serious immune diseases. The stake, about 10,406 shares worth roughly $245,000, surfaced in a routine 13F filing covering the second quarter, one of the many periodic disclosures through which the market quietly reveals where its patient capital is going. Set against a company still losing money and building its future on an experimental self-injected drug, the move re
Perigon Wealth Management Discloses New Stake in Vera Therapeutics Amid Mixed Analyst Outlook
Institutions in aggregate own 99.21% of the stock.
Mark
Why does a $245,000 position deserve any attention at all?
Mimi
On its own it doesn't. It's one of several filings showing institutions adding to Vera, and that's the real pattern here.
Luke
Careful, though. Some of these are second-quarter moves and others are first-quarter. They aren't one synchronized wave.
Mark
The stock sits well above its moving averages. What does that suggest?
Mimi
It's up from the roughly $23 average to $29.06, though still far below the 52-week high of $51.61.
Luke
That's a description of price, not an explanation. The filing doesn't say why anyone bought.
Mark
The last earnings were a miss, right?
Mimi
Yes, a $1.20 loss per share against an expected $0.82. Yet most analysts stay positive.
Luke
And the $63 consensus target is MarketBeat's aggregate. JPMorgan, for one, actually lowered its target to $53.
Mark
So what decides this?
Mimi
Atacicept. The Phase III trial in IgA nephropathy is the lead program.
Luke
Right, and nothing in this report tells us how that trial is going. That's still unknown.
O Pulso
- A small wealth firm's new Vera stake surfaced in a 13F filing, drawing attention to a stock that has been moving fast.
- Vera missed earnings estimates with a $1.20 per share loss against an expected $0.82, widening doubts about near-term profitability.
- The shares opened near $29, far above their 50-day and 200-day averages, while institutions already own nearly all outstanding stock.
- Analysts lean bullish, with a Moderate Buy consensus and a $63 average target, though one firm stays cautious.
- Everything now turns on the Phase III atacicept trial for IgA nephropathy, the event most likely to move the price.
In the quiet ledgers of institutional ownership, a modest Pittsburgh-style wealth firm, Perigon Wealth Management, has taken a small position in Vera Therapeutics, a clinical-stage biotechnology company working on treatments for serious immune diseases. The stake, about 10,406 shares worth roughly $245,000, surfaced in a routine 13F filing covering the second quarter, one of the many periodic disclosures through which the market quietly reveals where its patient capital is going. Set against a company still losing money and building its future on an experimental self-injected drug, the move reads less as a bold wager than as one more small hand reaching toward a long, uncertain promise.
A small wealth management firm, Perigon Wealth Management, has appeared in the shareholder records of Vera Therapeutics. Its latest 13F filing shows it bought 10,406 shares during the second quarter, a position worth about $245,000. It is a modest entry in a larger picture of institutional activity, where other firms have opened or expanded their own holdings, and where institutions together own nearly all of the company.
The stock itself is an animated story. Vera opened at $29.06 and carries a market value of about $1.85 billion, having traded between $18.53 and $51.61 over the past year. Its recent quarterly report brought a loss of $1.20 per share, wider than the $0.82 analysts had expected, and the company is not yet profitable.
Still, the professional view remains largely hopeful. Most analysts rate the shares a Buy, and the average target sits at $63. Vera is developing atacicept, an injectable treatment for serious immune conditions, and its progress through late-stage trials is what investors will watch most closely in the months ahead.
A small wealth management firm has shown up in the shareholder records of a clinical-stage biotech. Perigon Wealth Management LLC disclosed in its most recent 13F filing with the Securities and Exchange Commission that it bought a new stake in Vera Therapeutics (NASDAQ:VERA) during the second quarter. The position is 10,406 shares, valued at roughly $245,000.
Perigon was not alone in moving. Fifth Third Bancorp also opened a new position in the second quarter, worth about $102,000. Other filings cover the first quarter. Rhumbline Advisers raised its holdings by 7.9%, adding 4,600 shares, and now owns 63,189 shares worth $1,518,000. Jane Street Group increased its stake by 297.1%, buying 62,678 more shares, and now holds 41,578 shares valued at $999,000. UBS Asset Management Americas lifted its position by 22.4%, adding 17,907 shares, for a total of 98,013 shares worth $2,354,000. Dynamic Technology Lab Private Ltd opened a new first-quarter position valued at $326,000. Institutions in aggregate own 99.21% of the stock.
The share price gives these positions context. VERA opened at $29.06 on Wednesday, up 0.6%, which puts its market capitalization at $1.85 billion. Over the past 52 weeks it has traded between $18.53 and $51.61. Its 50-day moving average is $23.00 and its 200-day average is $23.04, so the stock is sitting well above both. The company shows a PE ratio of -8.12, a beta of 1.17, a quick and current ratio of 17.03, and a debt-to-equity ratio of 0.16.
The negative PE reflects the company's earnings. Vera last reported on Tuesday, August 5th, posting a loss of $1.20 per share. Consensus had been for a loss of $0.82, so the result missed by $0.38. A year earlier the loss was $0.62 per share. Analysts expect a full-year loss of $2.89 per share.
Analyst opinion remains largely favorable. Cantor Fitzgerald reissued an overweight rating on September 18th. JPMorgan Chase trimmed its price target from $56 to $53 on August 7th while keeping an overweight rating. Scotiabank reissued an outperform rating on June 3rd, and Guggenheim reiterated a buy the same day. Wolfe Research is the cooler voice, reaffirming a peer perform rating on August 4th. Across the coverage, seven analysts rate the stock a Buy and two rate it a Hold. MarketBeat puts the consensus at Moderate Buy with an average target price of $63.00.
What the company does explains the attention. Vera is a clinical-stage biotechnology firm developing treatments for serious immunological diseases. Its lead candidate, atacicept, is a fusion protein that patients self-inject under the skin. It is in a Phase III trial for immunoglobulin A nephropathy and in a Phase II trial for lupus nephritis.
For readers tracking the stock, the quarterly filings show who is buying, while the trial results will matter more to the price. Progress in the Phase III atacicept program is the thing to watch.
Citações Notáveis
JPMorgan cut its Vera price target from $56 to $53 but kept an overweight rating.— JPMorgan Chase & Co. research note, August 7th
Quer a matéria completa?
Leia o original em ETF Daily News ↗
Economy & Finance